TherVacB

N/A

Report date: 2025/03/20 10:04:51

Base Information

Drug NameTherVacB
Drug Alias NameN-Acetylgalactosamine-siRNA/shRNA-expressing adeno-associated virus vector (Alnylam Pharmaceuticals/Technical University of Helmholtz/University of Heidelberg)combinatorial RNAi/vaccination therapy
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesHelmholtz Zentrum MuenchenTechnical University Of MunichHeidelberg University +[4] 
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A